Business
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Pha
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below：","length":847,"tagName":"p"},{"type":"text","content":"Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Abstract #：306-OR Presentation Form: Oral presentationTime: 2025 June 23, 14:15 PM – 14:30 PM（CST）Presenter: Dr. Lei Qian, Innovent Biologics","length":232,"tagName":"p"},{"type":"text","content":"Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #：1886-LBPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Dr. Decheng Ren, Innovent Biologics","length":289,"tagName":"p"},{"type":"text","content":"Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat AccumulationAbstract #：777-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Dr.Tianpei Hong, Peking University Third Hospital","length":358,"tagName":"p"},{"type":"text","content":"Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and MicrobiomeAbstract #：1616-P Presentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University","length":278,"tagName":"p"},{"type":"text","content":"Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Me...